The US Surgeon General Vivek Murthy recently warned of a loneliness epidemic hitting the country. TT Capital Partners, a Bloomington, Minnesota-based private equity firm is stepping up to the table ...

PYXS has initiated dosing with PYX-201 in a phase 1 study, with preliminary results due in early 2024. PYXS expects to initiate dosing in a phase 1 study of PYX-106 in Q2'23, which could add ...

Pyxis Oncology is developing antibodies and antibody-drug conjugates for various tumor types. Initial data from the phase 1 trials of PYX-106 and PYX-201 are now expected in H2'24 and fall 2024 ...

Pyxis Oncology, Inc. is reallocating its resources to focus on the development of its leading asset, PYX-201, a pioneering antibody-drug conjugate (ADC) showing promising efficacy in treating head and ...

Pyxis Oncology announces Phase 1/2 trials for PYX-201, combining it with KEYTRUDA® to treat advanced solid tumors. Pyxis Oncology, Inc. has announced the initiation of two significant clinical trials ...

Pyx Health has raised $1.8 million to support the growth of an app it designed to help patients at risk of loneliness or social isolation following hospitalization or some other health event.

In today's hyper-interconnected world, we're all reminded how immediate everything can be with the simple tap of the finger. While we can grocery shop, prepare our taxes, or even be matched with a ...